TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05239546: Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers

Sponsor: University of Iowa · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 25 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$7,253,400

Rescue Site Savings

+$4,804,800

Unlock Full NCT05239546 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05239546 Rescue Dossier →